Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Stephen E. Sallan, MD


Pediatric Hematology/Oncology

Make an Appointment
Watch Video

Physician

  • Institute Physician
  • Quick Family Chair in Pediatric Oncology
  • Professor of Pediatrics, Harvard Medical School

Clinical Interests

  • Acute lymphoblastic leukemia (ALL)

Contact Information

  • Appointments888-733-4662 (new)
    617-632-3270 (established)
  • Office Phone Number617-632-3316
  • Fax617-632-5511

Bio

Dr. Sallan received his MD from Wayne State University School of Medicine in 1967. He completed residencies in pediatrics at the Boston Floating Hospital (1968), Children's Hospital of Philadelphia (1969), and the Hospital for Sick Children, London (1970). In 1972, he served as a fellow in pediatric oncology at Children's Hospital and DFCI, where he joined the staff in 1975. He was named chief of staff and chairman of the Medical Staff Executive Committee in 1995, and chief of staff emeritus in 2012.

Board Certification:

  • Pediatrics

Fellowship:

  • Boston Children's Hospital/Dana-Farber Cancer Institute, Pediatric Hematology/Oncology

Residency:

  • Children's Hospital of Philadelphia
  • Hospital for Sick Children, London, England

Medical School:

  • Wayne State University School of Medicine

Recent Awards:

  • Distinguished Alumni Award, Wayne State University School of Medicine 1997
  • James Carreras Prize for International Pediatrician of the Year 1987

Research

Acute Lymphoblastic Leukemia and Pediatric Brain Tumors

Acute lymphoblastic leukemia (ALL) is the most common malignancy of childhood. Investigators at DFCI have led the field of research in this disease for over 50 years, and our long-term results are currently the best in the world, with more than 80% of affected children remaining free of disease. The challenges are twofold: to recognize and develop better treatments for the other 20%, and to decrease the long-term toxicities associated with therapy. Our laboratory and clinical research focuses on the genetic heterogeneity of ALL, understanding the reasons for disease recurrence and drug resistance, developing new, more specific therapies (including tumor vaccines), and conducting all such research in the context of diminishing the toxicity of treatment. Current endeavors expand our investigations to adults with ALL and also extend the laboratory discoveries to other malignancies including lymphoma and adult cancer.Brain tumors are the second most common malignancies of childhood and have become the most common cause of death in children with cancer. The treatment of such patients requires a diverse team with expertise in pediatric oncology, neurosurgery, neuroradiology, neuropathology, neurology, radiation oncology, and many supportive care services. Our specialized team conducts clinical investigations that include innovative chemotherapy. For example, we focus on ways to interrupt tumor blood supplies (antiangiogenesis) and on specialized forms of radiation therapy that spare normal brain tissue while delivering high doses of toxic treatment to the tumor. In addition, brain tumor tissue from our patients is under active investigation in our neuro-oncology laboratory programs. Recently, we discovered that one relatively common type of childhood brain tumor, medulloblastoma, has a previously unrecognized molecular marker called TRK-C, and the likelihood of cure is directly related to the presence or absence of that marker.

Efficacy and Toxicity of Pegaspargase and Calaspargase Pegol in Childhood Acute Lymphoblastic Leukemia: Results of DFCI 11-001. J Clin Oncol. 2021 Jul 06; JCO2003692.
View in: PubMed

Genetic ancestry and skeletal toxicities among childhood acute lymphoblastic leukemia patients in the DFCI 05-001 cohort. Blood Adv. 2021 01 26; 5(2):451-458.
View in: PubMed

Corrigendum. Pediatr Blood Cancer. 2021 Mar; 68(3):e28885.
View in: PubMed

Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: Results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer. 2021 01; 68(1):e28719.
View in: PubMed

HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium. Pharmacogenomics. 2020 06; 21(8):541-547.
View in: PubMed

Protective Effects of Dietary Intake of Antioxidants and Treatment-Related Toxicity in Childhood Leukemia: A Report From the DALLT Cohort. J Clin Oncol. 2020 07 01; 38(19):2151-2159.
View in: PubMed

An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. JNCI Cancer Spectr. 2020 Apr; 4(2):pkz094.
View in: PubMed

Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients. Pharmacogenomics. 2019 11; 20(17):1189-1197.
View in: PubMed

Fluctuations in dietary intake during treatment for childhood leukemia: A report from the DALLT cohort. Clin Nutr. 2019 12; 38(6):2866-2874.
View in: PubMed

PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med. 2018 12 03; 215(12):3094-3114.
View in: PubMed

Health Status and Health-related Quality of Life Measurement in Pediatric Cancer Clinical Trials: An Examination of the DFCI 00-01 Acute Lymphoblastic Leukemia Protocol. J Pediatr Hematol Oncol. 2018 11; 40(8):580-587.
View in: PubMed

Genomic and clinical characterization of B/T mixed phenotype acute leukemia reveals recurrent features and T-ALL like mutations. Am J Hematol. 2018 11; 93(11):1358-1367.
View in: PubMed

Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. Blood Adv. 2018 06 26; 2(12):1449-1458.
View in: PubMed

Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001. Pediatr Blood Cancer. 2018 10; 65(10):e27256.
View in: PubMed

Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 08; 65(8):e27082.
View in: PubMed

Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 07; 65(7):e27062.
View in: PubMed

Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. Leukemia. 2018 10; 32(10):2126-2137.
View in: PubMed

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. Blood Adv. 2018 03 13; 2(5):529-533.
View in: PubMed

Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia. Int J Lab Hematol. 2018 Jun; 40(3):343-351.
View in: PubMed

The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. J Thromb Thrombolysis. 2018 Feb; 45(2):306-314.
View in: PubMed

Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2018 05; 65(5):e26952.
View in: PubMed

Influence of BCL2L11 polymorphism on osteonecrosis during treatment of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2019 02; 19(1):33-41.
View in: PubMed

An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001. Pediatr Blood Cancer. 2018 03; 65(3).
View in: PubMed

Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. Oncotarget. 2017 Jul 04; 8(27):43752-43767.
View in: PubMed

A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia. Pediatr Blood Cancer. 2017 Jul; 64(7).
View in: PubMed

Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2017 01; 17(1):107.
View in: PubMed

Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer. 2016 Dec 01; 122(23):3632-3640.
View in: PubMed

How Variable Is Our Delivery of Information? Approaches to Patient Education About Oral Chemotherapy in the Pediatric Oncology Clinic. J Pediatr Health Care. 2017 Jan - Feb; 31(1):e1-e6.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in: PubMed

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in: PubMed

Dietary intake and childhood leukemia: The Diet and Acute Lymphoblastic Leukemia Treatment (DALLT) cohort study. Nutrition. 2016 Oct; 32(10):1103-1109.e1.
View in: PubMed

Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol. 2016 Mar; 91(3):322-9.
View in: PubMed

Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer. 2016 Mar 15; 122(6):946-53.
View in: PubMed

Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec; 16(16):1677-90.
View in: PubMed

Children's Cancer and Environmental Exposures: Professional Attitudes and Practices. J Pediatr Hematol Oncol. 2015 Oct; 37(7):491-7.
View in: PubMed

Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J. 2016 11; 16(6):530-535.
View in: PubMed

Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41.
View in: PubMed

Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia. J Clin Oncol. 2015 Jul 01; 33(19):2205-11.
View in: PubMed

Cardiovascular disease in adult survivors of childhood cancer. Annu Rev Med. 2015; 66:161-76.
View in: PubMed

Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science. 2014 Dec 12; 346(6215):1373-7.
View in: PubMed

Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers. Paediatr Drugs. 2014 Oct; 16(5):373-89.
View in: PubMed

Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. Br J Haematol. 2015 Jan; 168(2):230-8.
View in: PubMed

Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar; 29(3):526-34.
View in: PubMed

Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014 Sep; 4(9):1074-87.
View in: PubMed

Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia. Clin Cancer Res. 2015 Jan 15; 21(2):329-34.
View in: PubMed

Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. Pharmacogenomics. 2014 Jun; 15(8):1105-16.
View in: PubMed

Report on the international colloquium on cardio-oncology (rome, 12-14 march 2014). Ecancermedicalscience. 2014; 8:433.
View in: PubMed

Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation. Nat Genet. 2014 Jun; 46(6):618-23.
View in: PubMed

Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun. 2014 Mar 24; 5:3469.
View in: PubMed

Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia. Leukemia. 2014 Sep; 28(9):1819-27.
View in: PubMed

c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood. 2014 Feb 13; 123(7):1040-50.
View in: PubMed

Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation. 2013 Oct 22; 128(17):1927-95.
View in: PubMed

Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia. Haematologica. 2014 Feb; 99(2):314-21.
View in: PubMed

Therapeutic approaches to haematological malignancies in adolescents and young adults. Br J Haematol. 2014 Jan; 164(1):3-14.
View in: PubMed

Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia. Clin Cancer Res. 2013 Sep 15; 19(18):5240-9.
View in: PubMed

Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. Cancer. 2013 Oct 01; 119(19):3555-62.
View in: PubMed

Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01. Pediatr Blood Cancer. 2013 Nov; 60(11):1785-91.
View in: PubMed

Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013 Mar 20; 31(9):1202-10.
View in: PubMed

Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes. Pediatrics. 2012 Dec; 130(6):1003-11.
View in: PubMed

Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res. 2012 Oct 15; 18(20):5773-9.
View in: PubMed

Functional and structural differences in the hippocampus associated with memory deficits in adult survivors of acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013 Feb; 60(2):293-300.
View in: PubMed

Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2012 Jul; 34(5):395-7.
View in: PubMed

Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Nov; 59(5):925-7.
View in: PubMed

Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012 Apr 01; 30(10):1042-9.
View in: PubMed

Health-related quality of life among children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Oct; 59(4):717-24.
View in: PubMed

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012 Feb 13; 209(2):259-73.
View in: PubMed

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33.
View in: PubMed

ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood. 2011 Nov 24; 118(22):5883-90.
View in: PubMed

The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood. 2011 Oct 13; 118(15):4169-73.
View in: PubMed

Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years post-diagnosis. Pediatr Blood Cancer. 2012 May; 58(5):758-65.
View in: PubMed

Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. PLoS One. 2011; 6(6):e20787.
View in: PubMed

Changes in cardiovascular signaling proteins during doxorubicin treatment in children with high-risk ALL. J Clin Oncol. 2011 May 20; 29(15_suppl):9551.
View in: PubMed

Impact of HFE mutations on cardiac status in survivors of childhood high-risk ALL: Dana-Farber Cancer Institute Childhood ALL 05-159. J Clin Oncol. 2011 May 20; 29(15_suppl):9508.
View in: PubMed

Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Pediatr Blood Cancer. 2011 Sep; 57(3):492-8.
View in: PubMed

The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer. 2011 Jun; 47(9):1373-9.
View in: PubMed

Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 2011 Apr 01; 71(7):2686-96.
View in: PubMed

Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors. Exp Hematol. 2011 Apr; 39(4):457-472.e3.
View in: PubMed

The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011 Feb; 152(4):452-9.
View in: PubMed

Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010 Oct; 11(10):950-61.
View in: PubMed

Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3816-23.
View in: PubMed

Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010 Feb; 54(2):199-205.
View in: PubMed

Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010 Apr 08; 115(14):2845-51.
View in: PubMed

Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia. 2010 Feb; 24(2):320-34.
View in: PubMed

Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010 Feb 18; 115(7):1351-3.
View in: PubMed

Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood. 2010 Feb 04; 115(5):1018-25.
View in: PubMed

DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia. Clin Cancer Res. 2009 Nov 15; 15(22):6931-8.
View in: PubMed

Treating childhood leukemia without cranial irradiation. N Engl J Med. 2009 Sep 24; 361(13):1310; author reply 1311-2.
View in: PubMed

Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009 Aug; 53(2):162-7.
View in: PubMed

Gender differences in long-term dexrazoxane cardioprotection in doxorubicin-treated children with acute lymphoblastic leukemia. J Clin Oncol. 2009 May 20; 27(15_suppl):10005.
View in: PubMed

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009 Jul 16; 114(3):647-50.
View in: PubMed

Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood. 2008 Jun 15; 111(12):5515-23.
View in: PubMed

Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008 Mar 01; 26(7):1106-11.
View in: PubMed

BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood. 2008 Feb 15; 111(4):2300-9.
View in: PubMed

Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. J Clin Oncol. 2007 Nov 01; 25(31):4914-21.
View in: PubMed

Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood. 2007 Sep 01; 110(5):1607-11.
View in: PubMed

Post-irradiation meningioma with sarcoidosis. J Neurooncol. 2007 May; 82(3):271-2.
View in: PubMed

Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol. 2007 Mar 01; 25(7):813-9.
View in: PubMed

Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood. 2007 May 01; 109(9):3929-35.
View in: PubMed

Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell. 2006 Oct; 10(4):331-42.
View in: PubMed

Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007 Feb 01; 109(3):896-904.
View in: PubMed

Outcome of adolescents with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocols, 1991-2000. J Clin Oncol. 2006 Jun 20; 24(18_suppl):9023.
View in: PubMed

Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival. Exp Hematol. 2006 May; 34(5):610-21.
View in: PubMed

Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood. 2006 Jun 01; 107(11):4508-13.
View in: PubMed

Silencing of the tumor suppressor gene FHIT is highly characteristic for MLL gene rearranged infant acute lymphoblastic leukemia. Leukemia. 2006 Feb; 20(2):264-71.
View in: PubMed

Myths and lessons from the adult/pediatric interface in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2006; 128-32.
View in: PubMed

Wise up: do not do it without protection! Pediatr Blood Cancer. 2005 Dec; 45(7):872-3.
View in: PubMed

Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res. 2005 Nov 01; 65(21):10050-8.
View in: PubMed

Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. Br J Haematol. 2005 Oct; 131(2):185-92.
View in: PubMed

Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood. 2005 Oct 01; 106(7):2484-90.
View in: PubMed

Cardiac changes associated with growth hormone therapy among children treated with anthracyclines. Pediatrics. 2005 Jun; 115(6):1613-22.
View in: PubMed

Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia. Blood. 2005 Sep 01; 106(5):1749-54.
View in: PubMed

Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005 Apr 20; 23(12):2629-36.
View in: PubMed

Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol. 2005 Apr 20; 23(12):2735-43.
View in: PubMed

Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol. 2005 Mar; 33(3):286-94.
View in: PubMed

Echocardiographic (Echo) monitoring of myocardial injury during doxorubicin (DOX) therapy for childhood acute lymphoblastic leukemia (ALL). J Clin Oncol. 2004 Jul 15; 22(14_suppl):8505.
View in: PubMed

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004 Jul 08; 351(2):145-53.
View in: PubMed

Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity. J Clin Oncol. 2004 Jul 01; 22(13):2701-7.
View in: PubMed

Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis. Blood. 2004 Jun 15; 103(12):4602-9.
View in: PubMed

FLT3 mutations in childhood acute lymphoblastic leukemia. Blood. 2004 May 01; 103(9):3544-6.
View in: PubMed

IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. Blood. 2004 Mar 01; 103(5):1891-900.
View in: PubMed

Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003 Oct 01; 21(19):3616-22.
View in: PubMed

Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection. Blood. 2003 Dec 15; 102(13):4520-6.
View in: PubMed

Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment. J Clin Oncol. 2003 Aug 01; 21(15):2953-60.
View in: PubMed

Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment. Curr Opin Hematol. 2003 Jul; 10(4):290-6.
View in: PubMed

Coincident expression of the chemokine receptors CCR6 and CCR7 by pathologic Langerhans cells in Langerhans cell histiocytosis. Blood. 2003 Apr 01; 101(7):2473-5.
View in: PubMed

Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia. 2003 Apr; 17(4):700-6.
View in: PubMed

Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 2003 Jul 01; 102(1):262-8.
View in: PubMed

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003 Feb; 3(2):173-83.
View in: PubMed

Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002 Dec 01; 20(23):4517-22.
View in: PubMed

Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol. 2002 Mar 15; 20(6):1677-82.
View in: PubMed

Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. J Clin Oncol. 2002 Jan 01; 20(1):237-46.
View in: PubMed

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002 Jan; 30(1):41-7.
View in: PubMed

Chemoattractants MDC and TARC are secreted by malignant B-cell precursors following CD40 ligation and support the migration of leukemia-specific T cells. Blood. 2001 Aug 01; 98(3):533-40.
View in: PubMed

Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer. 2001 Jul 01; 92(1):15-22.
View in: PubMed

Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol. 2001 Jun 15; 19(12):3066-72.
View in: PubMed

International Childhood Acute Lymphoblastic Leukemia Workshop: Sausalito, CA, 30 November-1 December 2000. Leukemia. 2001 May; 15(5):707-15.
View in: PubMed

Management of acute tumor lysis syndrome. Semin Oncol. 2001 Apr; 28(2 Suppl 5):9-12.
View in: PubMed

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001 Mar 01; 97(5):1211-8.
View in: PubMed

Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol. 2001 Feb 15; 19(4):1040-6.
View in: PubMed

Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000 Dec; 14(12):2247-56.
View in: PubMed

Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. Leukemia. 2000 Dec; 14(12):2193-4.
View in: PubMed

Translocation (2;8)(p12;q24) associated with a cryptic t(12;21)(p13;q22) TEL/AML1 gene rearrangement in a child with acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2000 Oct 15; 122(2):79-82.
View in: PubMed

Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. J Pediatr Hematol Oncol. 2000 May-Jun; 22(3):206-13.
View in: PubMed

Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer. 2000 Apr 15; 88(8):1964-9.
View in: PubMed

Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies. Blood. 1999 Nov 15; 94(10):3531-40.
View in: PubMed

Induction failure in acute lymphoblastic leukemia of childhood. Cancer. 1999 Mar 15; 85(6):1395-404.
View in: PubMed

Prognostic significance of early response to a single dose of asparaginase in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 1999 Jan-Feb; 21(1):6-12.
View in: PubMed

Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood. 1998 Dec 15; 92(12):4792-7.
View in: PubMed

Second malignancies in patients treated for childhood acute lymphoblastic leukemia. J Clin Oncol. 1998 Aug; 16(8):2848-53.
View in: PubMed

Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia. J Clin Oncol. 1998 Feb; 16(2):545-50.
View in: PubMed

Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Cancer. 1997 Dec 15; 80(12):2285-95.
View in: PubMed

Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997 Oct 21; 96(8):2641-8.
View in: PubMed

Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood. 1997 Oct 15; 90(8):2962-8.
View in: PubMed

Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells. Blood. 1997 Jul 15; 90(2):549-61.
View in: PubMed

Asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Blood. 1997 Mar 15; 89(6):1886-95.
View in: PubMed

Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997 Mar; 150(3):815-21.
View in: PubMed

TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996 Dec 01; 88(11):4252-8.
View in: PubMed

NCCN pediatric acute lymphoblastic leukemia practice guidelines. The National Comprehensive Cancer Network. Oncology (Williston Park). 1996 Dec; 10(12):1787-94.
View in: PubMed

Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31.
View in: PubMed

Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 1996 Jul 01; 88(1):41-8.
View in: PubMed

Relapsed acute lymphoblastic leukemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children. Bone Marrow Transplant. 1996 May; 17(5):763-8.
View in: PubMed

Uniform criteria for childhood acute lymphoblastic leukemia risk classification. J Clin Oncol. 1996 Feb; 14(2):680-1.
View in: PubMed

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996 Jan; 14(1):18-24.
View in: PubMed

[Results of treatment protocols apropos of thr Boston program]. Arch Pediatr. 1996; 3 Suppl 1:201s-203s.
View in: PubMed

The oral health of long-term survivors of acute lymphoblastic leukaemia: a comparison of three treatment modalities. Eur J Cancer B Oral Oncol. 1995 Jul; 31B(4):250-2.
View in: PubMed

Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med. 1995 06 29; 332(26):1738-43.
View in: PubMed

Neurobehavioral and neurologic outcome in long-term survivors of posterior fossa brain tumors: role of age and perioperative factors. J Child Neurol. 1995 May; 10(3):209-12.
View in: PubMed

Hemorrhagic vasculopathy after treatment of central nervous system neoplasia in childhood: diagnosis and follow-up. AJNR Am J Neuroradiol. 1995 Apr; 16(4):693-9.
View in: PubMed

Antiemetics in children receiving cancer chemotherapy. Support Care Cancer. 1994 Sep; 2(5):279-85.
View in: PubMed

Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet. 1994 Jul 09; 344(8915):82-6.
View in: PubMed

Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol. 1994 Apr; 12(4):740-7.
View in: PubMed

Biology and therapy of childhood acute lymphoblastic leukemia. Rev Invest Clin. 1994 Apr; Suppl:26-33.
View in: PubMed

Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation. 1994 Mar 15; 57(5):677-84.
View in: PubMed

Monitoring for anthracycline cardiotoxicity. Pediatrics. 1994 Mar; 93(3):433-7.
View in: PubMed

Interactions of steroid, methotrexate, and radiation determine neurotoxicity in an animal model to study therapy for childhood leukemia. Pediatr Res. 1994 Feb; 35(2):171-8.
View in: PubMed

Advances in radiation therapy for craniopharyngiomas. Pediatr Neurosurg. 1994; 21 Suppl 1:101-7.
View in: PubMed

Recent experience with Wilms' tumor: 1978-1991. Ann Surg Oncol. 1994 Jan; 1(1):59-65.
View in: PubMed

Infrequent mutation of the WT1 gene in 77 Wilms' Tumors. Hum Mutat. 1994; 3(3):212-22.
View in: PubMed

Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993 Sep; 11(9):1780-6.
View in: PubMed

Cardiovascular abnormalities in long-term survivors of childhood malignancy. J Clin Oncol. 1993 Jul; 11(7):1199-203.
View in: PubMed

Central nervous system treatment in childhood acute lymphoblastic leukemia. Long-term follow-up of patients diagnosed between 1973 and 1985. Cancer. 1993 Jul 01; 72(1):261-70.
View in: PubMed

Autologous bone marrow transplantation in childhood acute lymphoid leukemia with use of purging. Am J Pediatr Hematol Oncol. 1993 May; 15(2):162-8.
View in: PubMed

Prognostic factors in medulloblastoma, including DNA ploidy. J Clin Oncol. 1993 Apr; 11(4):616-22.
View in: PubMed

Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood. 1993 Mar 15; 81(6):1651-7.
View in: PubMed

Etanidazole as a modulator of combined modality therapy in the rat 9l-gliosarcoma. Int J Oncol. 1992 Nov; 1(6):625-30.
View in: PubMed

Incidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemia. Cancer. 1992 Oct 15; 70(8):2208-13.
View in: PubMed

Educational, occupational, and insurance status of childhood cancer survivors in their fourth and fifth decades of life. J Clin Oncol. 1992 Sep; 10(9):1397-406.
View in: PubMed

Extremely poor prognosis of pediatric acute lymphoblastic leukemia with translocation (9;22): updated experience. Leuk Lymphoma. 1992 Sep; 8(1-2):75-9.
View in: PubMed

Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer. 1992 Jul 01; 70(1):201-6.
View in: PubMed

The relationship of sex and treatment modality to neuropsychologic outcome in childhood acute lymphoblastic leukemia. J Clin Oncol. 1992 May; 10(5):810-7.
View in: PubMed

Fatal esophageal aspergilloma in a leukemic adolescent. Pediatr Infect Dis J. 1992 Mar; 11(3):245-7.
View in: PubMed

Changing antigen receptor gene rearrangements in a case of early pre-B cell leukemia: evidence for a tumor progenitor cell with stem cell features and implications for monitoring residual disease. Blood. 1992 Jan 15; 79(2):481-8.
View in: PubMed

Low-dose versus high-dose methotrexate during remission induction in childhood acute lymphoblastic leukemia (Protocol 81-01 update). Blood. 1991 Nov 15; 78(10):2514-9.
View in: PubMed

Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: The Berlin-Frankfurt-Münster and Dana-Farber Cancer Institute protocols. Ann Oncol. 1991 Nov-Dec; 2(10):745-9.
View in: PubMed

The change in patterns of relapse in medulloblastoma. Cancer. 1991 Oct 01; 68(7):1600-4.
View in: PubMed

Wilms' tumor patients with pulmonary metastases. Int J Radiat Oncol Biol Phys. 1991 Oct; 21(5):1187-93.
View in: PubMed

Improved survival for children with anaplastic Wilms' tumors. Cancer. 1991 Sep 01; 68(5):970-4.
View in: PubMed

201Tl/99mTc-HMPAO SPECT imaging of treated childhood brain tumors. Pediatr Neurol. 1991 Jul-Aug; 7(4):249-57.
View in: PubMed

The prognostic significance of postoperative residual tumor in ependymoma. Neurosurgery. 1991 May; 28(5):666-71; discussion 671-2.
View in: PubMed

Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991 Mar 21; 324(12):808-15.
View in: PubMed

Translocation (9;22) is associated with extremely poor prognosis in intensively treated children with acute lymphoblastic leukemia. Blood. 1991 Feb 01; 77(3):435-9.
View in: PubMed

Dentofacial development in long-term survivors of acute lymphoblastic leukemia. A comparison of three treatment modalities. Cancer. 1990 Dec 15; 66(12):2645-52.
View in: PubMed

Choroid plexus tumors in the breast cancer-sarcoma syndrome. Cancer. 1990 Dec 15; 66(12):2658-60.
View in: PubMed

Thyroid cancer in childhood. Endocrinol Metab Clin North Am. 1990 Sep; 19(3):649-62.
View in: PubMed

Surgery only for the treatment of patients with stage I (Cassady) Wilms' tumor. Cancer. 1990 Jul 15; 66(2):264-6.
View in: PubMed

Late effects of central nervous system treatment of acute lymphoblastic leukemia in childhood are sex-dependent. Dev Med Child Neurol. 1990 Mar; 32(3):238-48.
View in: PubMed

Sex differences in cognitive processing in children treated with CNS prophylaxis for acute lymphoblastic leukemia. J Pediatr Psychol. 1990 Feb; 15(1):105-22.
View in: PubMed

More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials. Haematol Blood Transfus. 1990; 33:459-66.
View in: PubMed

Pre-irradiation chemotherapy for infants and children with medulloblastoma: a preliminary report. J Neurosurg. 1989 Dec; 71(6):820-5.
View in: PubMed

Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol. 1989 Nov; 7(11):1594-601.
View in: PubMed

Prognostic implications of cytogenetic studies in an intensively treated group of children with acute lymphoblastic leukemia. Blood. 1989 Nov 01; 74(6):2130-5.
View in: PubMed

In vitro and in vivo killing of acute lymphoblastic leukemia cells by L-asparaginase. Cancer Res. 1989 Aug 01; 49(15):4363-8.
View in: PubMed

Hypertension in long-term survivors of childhood renal cancers. J Clin Oncol. 1989 Jul; 7(7):912-5.
View in: PubMed

Intravascular hemolysis and renal insufficiency after bone marrow transplantation. Blood. 1988 Aug; 72(2):451-5.
View in: PubMed

Pre-radiation chemotherapy for infants and poor prognosis children with medulloblastoma. Int J Radiat Oncol Biol Phys. 1988 Jul; 15(1):177-81.
View in: PubMed

Late onset of renal dysfunction in survivors of bone marrow transplantation. Int J Radiat Oncol Biol Phys. 1988 Jul; 15(1):99-104.
View in: PubMed

Medulloblastoma at the joint center for radiation therapy between 1968 and 1984. The influence of radiation dose on the patterns of failure and survival. Cancer. 1988 May 15; 61(10):1992-8.
View in: PubMed

Ophthalmic evaluation of survivors of acute lymphoblastic leukemia. Ophthalmology. 1988 Feb; 95(2):151-5.
View in: PubMed

Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complement. Cancer Treat Res. 1988; 38:265-83.
View in: PubMed

Brain tumors after cranial irradiation for childhood acute lymphoblastic leukemia. A 13-year experience from the Dana-Farber Cancer Institute and the Children's Hospital. Cancer. 1987 Apr 15; 59(8):1506-8.
View in: PubMed

Outcome of pregnancy in survivors of Wilms' tumor. JAMA. 1987 Jan 09; 257(2):216-9.
View in: PubMed

Monoclonal-antibody-purged autologous bone marrow transplantation for relapsed non-T-cell acute lymphoblastic leukemia in childhood. Haematol Blood Transfus. 1987; 31:67-74.
View in: PubMed

Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med. 1986 Sep 11; 315(11):657-63.
View in: PubMed

Human T-lymphotropic virus type III infection in previously immunocompromised hosts. J Clin Oncol. 1986 Apr; 4(4):540-3.
View in: PubMed

The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol. 1986; 14(4):211-5.
View in: PubMed

Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193). Cancer Res. 1985 Oct; 45(10):5169-72.
View in: PubMed

Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia. Semin Oncol. 1985 Jun; 12(2):122-30.
View in: PubMed

Use of trimethoprim-sulfamethoxazole to prevent bacterial infections in children with acute lymphoblastic leukemia. Pediatr Infect Dis. 1985 May-Jun; 4(3):265-9.
View in: PubMed

Renal cell carcinoma in childhood and adolescence: a clinical and pathological study of 17 cases. J Urol. 1985 May; 133(5):822-8.
View in: PubMed

Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res. 1985 Feb; 45(2):499-503.
View in: PubMed

Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: a 10-year experience. Semin Oncol. 1984 Dec; 11(4 Suppl 3):19-21.
View in: PubMed

Improved survival in neuroblastoma using multimodality therapy. Radiother Oncol. 1984 Oct; 2(3):189-200.
View in: PubMed

B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation. J Clin Invest. 1984 Aug; 74(2):332-40.
View in: PubMed

Preparation of human hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria meningitidis. Infect Immun. 1984 Jul; 45(1):248-54.
View in: PubMed

Neuroblastoma: the Joint Center for Radiation Therapy/Dana-Farber Cancer Institute/Children's Hospital experience. J Clin Oncol. 1984 Jul; 2(7):719-32.
View in: PubMed

Improved prognosis for infants with stage IV neuroblastoma. J Clin Oncol. 1984 Jul; 2(7):799-803.
View in: PubMed

Development of homozygosity for chromosome 11p markers in Wilms' tumour. Nature. 1984 May 10-16; 309(5964):172-4.
View in: PubMed

Combination chemotherapy in relapsed childhood acute lymphoblastic leukemia. Cancer Treat Rep. 1984 Feb; 68(2):411-2.
View in: PubMed

Characterization of glucocorticoid receptors in animal lymphoblastic disease: correlation with response to single-agent glucocorticoid treatment. Blood. 1984 Feb; 63(2):380-3.
View in: PubMed

Influence of local-regional lymph node metastases on prognosis in neuroblastoma. Med Pediatr Oncol. 1984; 12(4):260-3.
View in: PubMed

T-cell acute lymphoblastic leukaemia with late developing Philadelphia chromosome. Br J Haematol. 1984 Jan; 56(1):139-46.
View in: PubMed

Clinical applications of monoclonal antibodies in acute leukemia. Ann N Y Acad Sci. 1984; 428:308-17.
View in: PubMed

Second neoplasms after Wilms' tumor in childhood. J Natl Cancer Inst. 1983 Dec; 71(6):1205-9.
View in: PubMed

Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983 Nov; 43(11):5601-7.
View in: PubMed

Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res. 1983 Mar; 43(3):1389-94.
View in: PubMed

Breast carcinoma after cancer therapy in childhood. Cancer. 1983 Feb 01; 51(3):521-3.
View in: PubMed

Risk factors for thyroid abnormalities after neck irradiation for childhood cancer. Am J Med. 1983 Feb; 74(2):272-80.
View in: PubMed

Efficacy and morbidity of central nervous system "prophylaxis" in childhood acute lymphoblastic leukemia: eight years' experience with cranial irradiation and intrathecal methotrexate. Blood. 1983 Feb; 61(2):297-303.
View in: PubMed

Heterochromia iridis and Horner's syndrome due to paravertebral neurilemmoma. J Surg Oncol. 1983 Jan; 22(1):15-6.
View in: PubMed

In vitro treatment with monoclonal antibody prior to autologous bone marrow transplantation in acute lymphoblastic leukemia. Haematol Blood Transfus. 1983; 28:117-23.
View in: PubMed

Dysfunctional glucocorticoid receptors in acute leukemia. Haematol Blood Transfus. 1983; 28:142-5.
View in: PubMed

Cytogenetics of acute lymphoblastic leukaemia in children as a factor in the prediction of long-term survival. Br J Haematol. 1982 Nov; 52(3):389-99.
View in: PubMed

Clinical pharmacology of 9-beta-D-arabinofuranosyladenine in combination with 2'-deoxycoformycin. Cancer Res. 1982 Sep; 42(9):3884-6.
View in: PubMed

Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia. J Clin Invest. 1982 Aug; 70(2):433-42.
View in: PubMed

Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in-vitro treatment with J5 monoclonal antibody and complement. Lancet. 1982 Jul 10; 2(8289):60-3.
View in: PubMed

Pharmacokinetics of continuous intravenous and subcutaneous infusions of cytosine arabinoside. Blood. 1982 Jun; 59(6):1351-3.
View in: PubMed

Cancer chemotherapy-induced lactose malabsorption in children. Cancer. 1982 Feb 15; 49(4):646-50.
View in: PubMed

Late effects of treatment of cancer in infancy. Med Pediatr Oncol. 1982; 10(4):369-75.
View in: PubMed

Transdermal scopolamine in motion sickness. Pharmacotherapy. 1982 Jan-Feb; 2(1):29-31.
View in: PubMed

Clinical utility of leukemia cell terminal transferase measurements. Cancer Res. 1981 Nov; 41(11 Pt 2):4814-20.
View in: PubMed

Use of monoclonal antibodies as diagnostic and therapeutic reagents in acute lymphoblastic leukemia. Cancer Res. 1981 Nov; 41(11 Pt 2):4771-5.
View in: PubMed

Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia. Cancer Res. 1981 Nov; 41(11 Pt 1):4508-11.
View in: PubMed

The childhood leukemias. J Pediatr. 1981 Nov; 99(5):676-88.
View in: PubMed

Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia. Cancer Res. 1981 Sep; 41(9 Pt 1):3343-6.
View in: PubMed

Chromosomal findings in acute lymphoblastic leukaemia of childhood: an independent prognostic factor. Lancet. 1981 Aug 01; 2(8240):249-50.
View in: PubMed

Antiemetic effect of intramuscular levonantradol in patients receiving anticancer chemotherapy. J Clin Pharmacol. 1981 Aug-Sep; 21(S1):43S-50S.
View in: PubMed

Levonantradol for chemotherapy-induced emesis: phase I-II oral administration. J Clin Pharmacol. 1981 Aug-Sep; 21(S1):51S-56S.
View in: PubMed

Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood. 1981 Jul; 58(1):141-52.
View in: PubMed

Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children. Cancer. 1981 Jun 15; 47(12):2810-6.
View in: PubMed

Chronic pain: principles of management. J Pediatr. 1981 Feb; 98(2):180-9.
View in: PubMed

T-cell acute lymphoblastic leukemia in children. Haematol Blood Transfus. 1981; 26:121-3.
View in: PubMed

Relapse in childhood acute lymphoblastic leukemia after elective cessation of initial treatment: failure of subsequent treatment with cyclophosphamide, cytosine arabinoside, vincristine and prednisone (COAP). Med Pediatr Oncol. 1981; 9(5):455-62.
View in: PubMed

Is THC an effective antiemetic for cancer patients? Opinion 2. CA Cancer J Clin. 1980 Sep-Oct; 30(5):283-5.
View in: PubMed

Augmentation of vincristine neurotoxicity by irradiation of peripheral nerves. Cancer Treat Rep. 1980 Aug-Sep; 64(8-9):963-5.
View in: PubMed

Comparison of three methods of central-nervous-system prophylaxis in childhood acute lymphoblastic leukaemia. Lancet. 1980 Jun 28; 1(8183):1398-402.
View in: PubMed

Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood. 1980 Mar; 55(3):395-402.
View in: PubMed

Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med. 1980 Jan 17; 302(3):135-8.
View in: PubMed

Management of acute lymphoblastic and acute myeloblastic leukemia in childhood. Paediatrician. 1980; 9(2):56-67.
View in: PubMed

Leukemia-associated antigens in ALL. Blood. 1979 Dec; 54(6):1240-8.
View in: PubMed

Subset derivation of T-cell acute lymphoblastic leukemia in man. J Clin Invest. 1979 Aug; 64(2):392-7.
View in: PubMed

An autopsy study of eye involvement in acute leukemia of childhood. Med Pediatr Oncol. 1979; 6(2):171-7.
View in: PubMed

Dynamic parameters of membrane lipids in normal and leukemic human lymphocytes isolated from peripheral blood and bone marrow. Cancer Res. 1978 Dec; 38(12):4654-61.
View in: PubMed

Acute lymphoblastic leukemia: treatment. Cancer. 1978 Aug; 42(2 Suppl):828-38.
View in: PubMed

Actinomycin D in childhood acute lymphocytic leukemia. Cancer Treat Rep. 1978 May; 62(5):829-31.
View in: PubMed

Intermittent combination chemotherapy with adriamycin for childhood acute lymphoblastic leukemia: clinical results. Blood. 1978 Mar; 51(3):425-33.
View in: PubMed

A pathological study of eye involvement in acute leukemia of childhood. Trans Am Ophthalmol Soc. 1978; 76:90-101.
View in: PubMed

Selective erythroid aplasia during therapy for acute lymphoblastic leukemia. Pediatrics. 1977 Jun; 59(6):895-8.
View in: PubMed

Chemotherapy with cyclophosphamide, vincristine, cytosine arabinoside, and prednisone (COAP) in childhood acute lymphoblastic leukemia (ALL). Med Pediatr Oncol. 1977; 3(4):359-64.
View in: PubMed

Clinical and cytokinetic aspects of remission induction of childhood acute lymphoblastic leukemia (ALL): addition of an anthracycline to vincristine and prednisone. Med Pediatr Oncol. 1977; 3(3):281-7.
View in: PubMed

Development of an effective treatment program for childhood acute lymphocytic leukemia: a preliminary report. Med Pediatr Oncol. 1976; 2(2):157-66.
View in: PubMed

Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med. 1975 Oct 16; 293(16):795-7.
View in: PubMed

Peritoneal dialysis in maple syrup urine disease. Lancet. 1969 Dec 27; 2(7635):1423-4.
View in: PubMed

Research Departments:

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Dana 1642
Boston, MA 02215
Get Directions

Ratings

Top